| 三种乳腺癌化疗方案的药物经济学分析 |
| |
| 引用本文： | 徐素梅,吕淑河,王雨露,李岱,徐平声.三种乳腺癌化疗方案的药物经济学分析[J].中国现代应用药学,2018,35(2):271-274. |
| |
| 作者姓名： | 徐素梅 吕淑河 王雨露 李岱 徐平声 |
| |
| 作者单位： | 中南大学湘雅医院,中南大学湘雅医院,中南大学湘雅医院,中南大学湘雅医院,中南大学湘雅医院 |
| |
| 摘 要： | 目的 从药物经济学角度评价乳腺癌术后3种化疗方案的经济学效果,为临床合理用药提供参考。方法 90例乳腺癌术后患者分为3组(TAC、PEC、AC),采用药物经济学的成本-效果分析法对3种化疗方案进行临床病例的回顾性分析比较(T：多西他赛,A：多柔比星,C：环磷酰胺,P：紫杉醇脂质体,E：表柔比星)。结果 3组化疗方案的总体有效率分别为71.87%,73.07%,65.62%；治疗成本分别为11713.49元,18197.79元和7795.82元；成本-效果比分别为162.98,249.04,118.80。化疗不良反应方面,PEC组发生率高于TAC组及AC组,差异有显著性(P≤0.05)。结论 TAC为乳腺癌术后化疗较佳的治疗方案,值得推广。
|
| 关 键 词： | 成本-效果 药物经济学 乳腺癌 敏感度分析 |
| 收稿时间： | 2017/6/4 0:00:00 |
| 修稿时间： | 2018/1/26 0:00:00 |
Analysis of Pharmacoeconomic of Three Therapeutic Schemes for Mammary Cancer |
| |
| XU Sumei,LYU Shuhe,WANG Yulu,LI Dai and XU Pingsheng.Analysis of Pharmacoeconomic of Three Therapeutic Schemes for Mammary Cancer[J].The Chinese Journal of Modern Applied Pharmacy,2018,35(2):271-274. |
| |
| Authors: | XU Sumei LYU Shuhe WANG Yulu LI Dai and XU Pingsheng |
| |
| Affiliation: | National Institution of Drug Clinical Trail, Department of Pharmacy,Xiangya Hospital,Central South University,Changsha HU-NAN,Xiangya Hospital, Central South University,National Institution of Drug Clinical Trail, Department of Pharmacy,Xiangya Hospital,Central South University,Changsha HU-NAN,National Institution of Drug Clinical Trail, Department of Pharmacy,Xiangya Hospital,Central South University,Changsha HU-NAN,National Institution of Drug Clinical Trail, Department of Pharmacy,Xiangya Hospital,Central South University,Changsha HU-NAN |
| |
| Abstract: | OBJECTIVE To evaluate the cost-effectiveness of three chemotherapy schemes in postoperative treatment of mammary cancer, providing a basis for the further drug administration. METHODS Ninety postoperative patients with mammary cancer were divided into three groupsTAC group (docetaxel + doxorubicin + cyclophosphamide), PEC group (paclitaxel + epirubicin + cyclophosphamide), and AC group (doxorubicin + cyclophosphamide)], the cost-effectiveness method in pharmacoeconomics was adopted to analyze retrospectively the three different regimens.RESULTS The overall response rate for TAC, PEC and AC were 71.87%, 73.07% and 65.62%, respectively; the costs were 11 713.49, 18 197.79 and 7 795.82 yuan, respectively, with corresponding cost-effectiveness ratios of 162.98, 249.04 and 118.80. For the chemotherapy toxicity, the PEC group was higher than those of the TAC group and AC group. CONCLUSION Scheme TAC is a better approach for postoperative treatment of soaked mammary cancer. |
| |
| Keywords: | Cost-effectiveness analysis Pharmacoeconomics Mammary cancer Sensitivity analysis |
|
| 点击此处可从《中国现代应用药学》浏览原始摘要信息 |
|
点击此处可从《中国现代应用药学》下载全文 |
|
